Tissue-Engineered Skin (Apligraf) in the Healing of Patients With Epidermolysis Bullosa Wounds
The DOI matches its Crossref record.
Abstract
BACKGROUND: At present, wound treatment of inherited epidermolysis bullosa (EB) is only supportive. OBJECTIVE: To determine the safety and clinical effects of tissue-engineered skin (Apligraf; Organogenesis Inc, Canton, Mass) in the healing of wounds of patients with different types of EB. DESIGN: An open-label uncontrolled study of 15 patients with EB treated with tissue-engineered skin. Each patient received tissue-engineered skin on up to 2 wounds on each of 3 clinic visits: day 1, week 6, and week 12. They were evaluated 7 (+/- 3) days and 6 weeks after each round of treatment. A quality-of-life survey was administered during week 6. SETTING: University of Miami, Miami, Fla. PATIENTS: Volunteers with EB. MAIN OUTCOME MEASURE: Safety and wound healing. RESULTS: A total of 69 different acute wounds received tissue-engineered skin at the day-1 (24 wounds), week-6 (23 wounds), and week-12 (22 wounds) visits. Overall, 63 wounds (79%) were found healed at the day-7 visit. Of the acute wounds, 82% (51/62) were healed 6 weeks after being treated, 75% (27/36) after 12 weeks, and 79% (11/14) after 18 weeks. Nine chronic wounds were also treated. Four were healed at 6 weeks; however, 7 were still open at the last clinic visit (week 18). There were no signs of rejection or clinical infection and no adverse events related to the tissue-engineered skin. The quality of life for most patients improved after treatment. Compared with patients' recollection of wounds treated with standard dressings, healing was faster and less painful. CONCLUSION: In this series of patients, tissue-engineered skin induced very rapid healing, was not clinically rejected, and was devoid of adverse effects. It was felt by the patients and families to be more effective than conventional dressings for EB wounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Wound Healing: A Cellular Perspective
Rodrigues, M., Kosaric, N., Bonham, C. A., & Gurtner, G. C. (2019) · Physiological Reviews · doi:10.1152/physrev.00067.2017 · Cited by 3,013
Engineered skin substitutes: practices and potentials
Supp, D. M., & Boyce, S. T. (2005) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2004.07.023 · Cited by 520
Tissue-Engineered Skin: Current Status in Wound Healing
Bello, Y. M., Falabella, A. F., & Eaglstein, W. H. (2001) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200102050-00005 · Cited by 410
Self-citationWound Dressings: Selecting the Most Appropriate Type
Broussard, K. C., & Powers, J. G. (2013) · American Journal of Clinical Dermatology · doi:10.1007/s40257-013-0046-4 · Cited by 310
The role of fibroblasts in tissue engineering and regeneration
Wong, T., McGrath, J. A., & Navsaria, H. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07914.x · Cited by 304
Collagen—emerging collagen based therapies hit the patient
Abou Neel, E. A., Bozec, L., Knowles, J. C., Syed, O., Mudera, V., Day, R., & Hyun, J. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.08.010 · Cited by 296
“It is worth noting that about a quarter of the wounds treated with Apligraf® may present reblistering after healing which could be attributed to the replacement of the original cells present in the dressing by those of the patients, although in one particular case the duration and the severity of the blister was less…”
BackgroundZaulyanov, L., & Kirsner, R. S. (2007) · Clinical Interventions in Aging · doi:10.2147/ciia.2007.2.1.93 · Cited by 266
Falanga, V., & Faria, K. (2007) · Principles of Tissue Engineering · doi:10.1016/b978-012370615-7/50081-0 · Cited by 13
Metadata
- Authors
- Falabella, A. F., Valencia, I. C., Eaglstein, W. H., & Schachner, L. A.
- Venue
- Archives of Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2000-10-01
- Volume
- 136
- Issue
- 10
- Pages
- 1225-30
- ISSN
- 0003-987X (ISSN-L)
- OpenAlex
- W1987555596
- Cited by
- 176
- References
- 0
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.